All In Biotech

Drug Trial Radar · NCT02978326

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study Evaluating the Efficacy, Safety, and Pharmacokinetics of SAGE-217 in the Treatment of Adult Female Subjects With Severe Postpartum Depression

Last checked: Nov 20, 2026Latest source record: Dec 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 276 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

276

Actual

Start

Jan 4, 2017

Primary completion

Nov 15, 2018

Study completion Dec 11, 2018

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Nov 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose of this study was to determine if treatment with SAGE-217 reduces depressive symptoms in participants with severe postpartum depression (PPD) compared to placebo as assessed by the change from baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) total score at Day 15 and to evaluate the safety and tolerability of SAGE-217 compared to placebo as assessed by the incidence of adverse events, vital sign measurements, clinical laboratory evaluations, electrocardiogram (ECG) parameters, and the Columbia Suicide Severity Rating Scale (C-SSRS).

Conditions

  • Postpartum Depression

Interventions

  • SAGE-217 15/20 mg Oral SolutionDrug

    SAGE-217, 15 mg oral solution, BID for Days 1 to 2 followed by 20 mg oral solution BID for Days 3 to 14. If not tolerated, 15 mg for the rest of study (Days 3 to 14).

  • PlaceboDrug

    SAGE-217 matching placebo, capsules, orally, once daily, for up to 14 days.

  • SAGE 217 30 mg CapsulesDrug

    SAGE-217, 30 mg, capsules, orally, once daily, for up to 14 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Parts A and B: Change From Baseline in the 17-Item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15Time frame: Parts A and B: Baseline, Day 15

Locations

27 sites in 1 country. Site status is shown where the registry gives one.

  • Sage Investigational Site

    Little Rock, Arkansas

  • Sage Investigational Site

    Beverly Hills, California

  • Sage Investigational Site

    Oceanside, California

  • Sage Investigational Site

    Wildomar, California

  • Sage Investigational Site

    Washington D.C., District of Columbia

  • Sage Investigational Site

    Aventura, Florida

  • Sage Investigational Site

    Miami, Florida

  • Sage Investigational Site

    Orlando, Florida

  • Sage Investigational Site

    Pensacola, Florida

  • Sage Investigational SIte

    Pinellas Park, Florida

  • Sage Investigational Site

    Atlanta, Georgia

  • Sage Investigational Site

    Decatur, Georgia

  • Sage Investigational Site

    Hoffman Estates, Illinois

  • Sage Investigational Site

    Owensboro, Kentucky

  • Sage Investigational Site

    Lake Charles, Louisiana

  • Sage Investigational Site

    New Orleans, Louisiana

  • Sage Investigational Site

    Saint Charles, Missouri

  • Sage Investigational Site

    Las Vegas, Nevada

  • Sage Investigational Site

    Manhasset, New York

  • Sage Investigational Site

    New York, New York

  • Sage Investigational Site

    Chapel Hill, North Carolina

  • Sage Investigational Site

    Raleigh, North Carolina

  • Sage Investigational Site

    Providence, Rhode Island

  • Sage Investigational Site

    Fort Worth, Texas

  • Sage Investigational Site

    Houston, Texas

  • Sage Investigational Site

    Richardson, Texas

  • Sage Investigational Site

    Orem, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.